.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Express Scripts
Chinese Patent Office
Accenture
Cantor Fitzgerald
Chubb
Harvard Business School
Deloitte
Julphar
AstraZeneca

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,658,590

« Back to Dashboard

Which drugs does patent 5,658,590 protect, and when does it expire?


Patent 5,658,590 protects STRATTERA and is included in one NDA. There has been one Paragraph IV challenge on Strattera.

Protection for STRATTERA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 5,658,590

Title: Treatment of attention-deficit/hyperactivity disorder
Abstract:Tomoxetine, a norepinephrine uptake inhibitor, is used to treat attention-deficit/hyperactivity disorder.
Inventor(s): Heiligenstein; John H. (Indianapolis, IN), Tollefson; Gary D. (Indianapolis, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:08/371,341
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
LillySTRATTERAatomoxetine hydrochlorideCAPSULE;ORAL021411-001Nov 26, 2002DISCNNoNo► Subscribe► SubscribeY► Subscribe
LillySTRATTERAatomoxetine hydrochlorideCAPSULE;ORAL021411-002Nov 26, 2002ABRXYesNo► Subscribe► SubscribeY► Subscribe
LillySTRATTERAatomoxetine hydrochlorideCAPSULE;ORAL021411-003Nov 26, 2002ABRXYesNo► Subscribe► SubscribeY► Subscribe
LillySTRATTERAatomoxetine hydrochlorideCAPSULE;ORAL021411-004Nov 26, 2002ABRXYesNo► Subscribe► SubscribeY► Subscribe
LillySTRATTERAatomoxetine hydrochlorideCAPSULE;ORAL021411-005Nov 26, 2002ABRXYesNo► Subscribe► SubscribeY► Subscribe
LillySTRATTERAatomoxetine hydrochlorideCAPSULE;ORAL021411-006Nov 26, 2002ABRXYesYes► Subscribe► SubscribeY► Subscribe
LillySTRATTERAatomoxetine hydrochlorideCAPSULE;ORAL021411-007Feb 14, 2005ABRXYesNo► Subscribe► SubscribeY► Subscribe
LillySTRATTERAatomoxetine hydrochlorideCAPSULE;ORAL021411-008Feb 14, 2005ABRXYesNo► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Baxter
Colorcon
Healthtrust
US Department of Justice
Express Scripts
Moodys
Johnson and Johnson
Citi
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot